Phase 2 Study on Use of a Combination of Pemetrexed in Patients With Advanced Gastric Carcinoma

Phase 2CompletedNCT00190801

Eli Lilly and Company50 enrolled

Overview

Pemetrexed has shown an anti-tumor activity in advanced gastric cancer patients in a previous study, while cisplatin is widely used in the combination chemotherapy of gastric cancer. Pemetrexed has shown synergy with cisplatin in preclinical models and in various human cancers. The introduction of vitamin supplementation has made treatment with pemetrexed plus cisplatin safe and well tolerated. The present phase 2 study is an effort to determine the efficacy and safety of the combination of pemetrexed and cisplatin in Korean patients with gastric carcinoma who had no prior palliative chemotherapy for advanced disease. The patients, who will give their consent for participating in this study, will be screened for their eligibility and on meeting pre-defined study eligibility criteria, they will receive an intravenous therapy of the combination of pemetrexed and cisplatin for number of times that in the opinion of their treating physician is appropriate for them. A response rate of 30% is considered as the minimum activity level of interest for this patient population.

Study Type

INTERVENTIONAL

Allocation

NON_RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Gastrointestinal Neoplasms

Interventions

Eligibility

Sex: ALLMin age: 18 YearsMax age: 70 Years

Medical Language ↔ Plain English

Inclusion Criteria: * diagnosis of adenocarcinoma of the stomach * Stage IV disease not amenable to curative surgery. * Disease status must be that of measurable disease as defined by RECIST criteria * Performance Status of 0 or 1 on the ECOG Scale and adequate organ function. * Signed informed consent from patient Exclusion Criteria: * Prior palliative chemotherapy for advanced disease. * Known or suspected brain metastasis or Second primary malignancy that is clinically detectable at the time of consideration for study enrollment. * Concurrent administration of any other tumor therapy * Inability to interrupt aspirin or other nonsteroidal anti-inflammatory drugs (NSAIDs) 2 days before, the day of, and 2 days after the dose of ALIMTA plus cisplatin. * Inability or unwillingness to take folic acid, vitamin B12 supplementation, or dexamethasone.

Locations (3)

For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon-Fri from 9AM to 5PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

Goyang-si, South Korea

Incheon, South Korea

Seoul, South Korea

Outcomes

Primary Outcomes

Response rate according to RECIST criteria

Secondary Outcomes

The following time to event efficacy measures:

o Duration of overall response for responding patients

o Time to documented progressive disease

o Time to treatment failure

o Overall survival

The quantitative and qualitative toxicity of pemetrexed plus cisplatin in this patient population